2.42
전일 마감가:
$2.25
열려 있는:
$2.29
하루 거래량:
1.35M
Relative Volume:
0.82
시가총액:
$342.54M
수익:
-
순이익/손실:
$-35.47M
주가수익비율:
-4.2456
EPS:
-0.57
순현금흐름:
$-124.27M
1주 성능:
+8.04%
1개월 성능:
+3.42%
6개월 성능:
+299.01%
1년 성능:
+32.24%
Prokidney Corp Stock (PROK) Company Profile
명칭
Prokidney Corp
전화
336-999-7028
주소
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
PROK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
PROK
Prokidney Corp
|
2.42 | 318.48M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-16 | 개시 | H.C. Wainwright | Buy |
| 2025-06-30 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-30 | 개시 | JP Morgan | Neutral |
| 2024-09-10 | 개시 | Guggenheim | Buy |
| 2024-03-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-01-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-07-25 | 개시 | BTIG Research | Buy |
| 2022-12-21 | 개시 | Jefferies | Buy |
| 2022-11-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-10-18 | 개시 | UBS | Buy |
| 2022-10-14 | 개시 | Citigroup | Buy |
| 2022-09-23 | 개시 | BofA Securities | Buy |
| 2022-09-02 | 개시 | Evercore ISI | Outperform |
모두보기
Prokidney Corp 주식(PROK)의 최신 뉴스
Is ProKidney Corp. stock a buy on dipsDouble Top/Bottom Patterns & Rapid Profit Growth - ulpravda.ru
ProKidney (NASDAQ:PROK) Trading 6.9% HigherTime to Buy? - MarketBeat
ProKidney Corp. CEO Bruce Culleton to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
ProKidney Corp. (NASDAQ:PROK) Given Consensus Rating of "Hold" by Analysts - MarketBeat
ProKidney Shares Dip Following FDA Agreement on Rilparencel Approval Strategy - MSN
ProKidney (NASDAQ:PROK) Shares Down 7.3%Should You Sell? - MarketBeat
B of A Securities Downgrades ProKidney (PROK) - MSN
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - MSN
ProKidney Corp. (PROK) positioned to redefine chronic kidney disease treatment, believes HC Wainwright - MSN
ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright - Yahoo Finance
ProKidney (PROK) price target increased by 15.10% to 6.85 - MSN
ProKidney (PROK) Price Target Increased by 15.10% to 6.85 - Nasdaq
Is ProKidney Corp. stock attractive for growth ETFsWeekly Trade Recap & Weekly High Momentum Picks - Улправда
Will ProKidney Corp. stock maintain momentum in 2025Weekly Trend Recap & Weekly Momentum Stock Picks - Улправда
Is ProKidney Corp. stock attractive for passive investors2025 Trade Ideas & AI Driven Price Forecasts - Улправда
ProKidney (NASDAQ:PROK) Stock Price Down 4.3%What's Next? - MarketBeat
Will ProKidney Corp. stock outperform tech sector in 20252025 Performance Recap & Smart Swing Trading Alerts - DonanımHaber
Aug Breakouts: Is ProKidney Corp. stock a buy on dips2025 Top Decliners & High Return Trade Opportunity Guides - Улправда
HC Wainwright Weighs in on ProKidney FY2025 Earnings - MarketBeat
ProKidney initiated with a buy at HC Wainwright - MSN
ProKidney (NASDAQ:PROK) Stock Price Up 5.2%What's Next? - MarketBeat
ProKidney (NASDAQ:PROK) Coverage Initiated by Analysts at HC Wainwright - MarketBeat
Truliant, ProKidney sales top Triad commercial transactions for week of Dec. 12 - The Business Journals
HC Wainwright & Co. Initiates Coverage of ProKidney (PROK) with Buy Recommendation - Nasdaq
H.C. Wainwright initiates ProKidney stock with Buy rating, $12 target By Investing.com - Investing.com South Africa
ProKidney initiated with a Buy at H.C. Wainwright - TipRanks
HC Wainwright & Co. Initiates Coverage on ProKidney (PROK) with a Buy Rating | PROK Stock News - GuruFocus
HC Wainwright Initiates Coverage on ProKidney With Buy Rating, $12 Price Target - marketscreener.com
H.C. Wainwright initiates ProKidney stock with Buy rating, $12 target - Investing.com India
This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm
ProKidney Corp. (NASDAQ:PROK) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
ProKidney (NASDAQ:PROK) Trading Down 6.8%What's Next? - MarketBeat
Why ProKidney Corp. stock remains resilientJuly 2025 Earnings & Real-Time Volume Analysis - Newser
Promising Penny Stocks To Watch In December 2025 - simplywall.st
What drives ProKidney Corp stock priceCurrency Fluctuation Impact & Rapid Capital Trading Tips - earlytimes.in
ProKidney site sells Greensboro site for $6.5M less than it paid for property - The Business Journals
While insiders own 18% of ProKidney Corp. (NASDAQ:PROK), retail investors are its largest shareholders with 50% ownership - Yahoo Finance
ProKidney Corp. (PROK) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How ProKidney Corp. stock benefits from tech adoptionWeekly Volume Report & Smart Money Movement Alerts - newser.com
Will ProKidney Corp. stock beat EPS estimatesMarket Rally & Free Risk Controlled Daily Trade Plans - newser.com
What data driven models say about ProKidney Corp.’s futureQuarterly Market Summary & Weekly Stock Breakout Alerts - newser.com
What technical charts say about ProKidney Corp. stockJuly 2025 Levels & Low Drawdown Momentum Ideas - newser.com
What valuation multiples suggest for ProKidney Corp. stockJuly 2025 EndofMonth & Reliable Trade Execution Plans - newser.com
Is now a turning point for ProKidney Corp.Recession Risk & Fast Entry Momentum Trade Alerts - newser.com
What sentiment indicators say about ProKidney Corp. stock2025 Breakouts & Breakdowns & Free Expert Approved Momentum Trade Ideas - newser.com
Prokidney Corp (PROK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):